Presentation of new Lumakras CODEBREAK 200 CNS data at ASCO 2023 meeting – Amgen

Amgen announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. The research presented reinforces the efficacy of Lumakras/Lumykras (sotorasib) in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal […]